GlassScriptPhysician profile
Larry F Berman
NPI 1508869835
$10,877.06
in general payments reported to CMS, 2019-2025
52 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,730 · 2021: $1,458 · 2022: $1,827 · 2023: $2,024 · 2024: $1,534 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.68 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.41 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,365.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,110.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $637.99 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $534.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.23 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $471.46 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Cepheid | $450.00 | 2020 | |
| Astellas Pharma US INC | $424.91 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $415.80 | 2019-2024 | Trintellix, Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.45 | 2019-2024 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $369.22 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $326.92 | 2019-2024 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $285.13 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $212.13 | 2022 |
Show all 45 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.